Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Gut. 2015 Mar 16;65(6):925–934. doi: 10.1136/gutjnl-2014-308416

Figure 6. Knockdown of endogenous DARPP-32 expression decreases ANGPT2 protein level, xenograft tumor growth, and angiogenesis.

Figure 6

A) Western blot analysis of DARPP-32, ANGPT2, phospho-STAT3 (Y705) (P-STAT3) proteins in SNU-16 cells stably expressing DARPP-32 shRNA (DP32 shRNA) or scrambled shRNA (Scr shRNA). B) SNU-16 cells stably expressing DARPP-32 shRNA or scrambled shRNA were injected subcutaneously (2×106 cells per site) into nude mice. Tumor volume was measured at the indicated times; each data point represents the mean ± standard deviation for 10 xenografts. C) Western blot analysis of DARPP-32 and ANGPT2 proteins in SNU-16 xenograft tumor samples. D) Immunohistochemical staining of DARPP-32, ANGPT2, phosphor-STAT3 (Y705) and von Willebrand factor in SNU-16 xenograft tumors (100X), each sample was amplified to show the details. E) Quantification data for D), *P<0.05, **P<0.01, ***P<0.001 compared with SNU-16 scrambled shRNA cells (t test).